A SAFE (Simple Agreement for Future Equity) is an investment contract that gives you the right to receive equity shares in Epinal at a future date typically when the company raises its next priced funding round (Series A, Series B) or undergoes a liquidity event (acquisition or IPO).

The minimum investment is $100. There is no maximum limit you can invest as much as you're comfortable with, up to the campaign's $2M maximum raise

You make money when Epinal undergoes a liquidity event, such as: Acquisition: A larger company (e.g., Abbott, Dräger, Thermo Fisher) acquires Epinal. Your SAFE converts to equity, and you receive cash or stock based on the acquisition terms. IPO: Epinal goes public, and your shares become tradeable on public markets. Secondary sale: In some cases, investors may have opportunities to sell shares in private secondary markets before an IPO (typically after Series B/C rounds).

Like all early-stage investments, investing in Epinal carries significant risk. Potential risks include: Product development delays: FDA approval and field trial timelines may take longer than expected. Regulatory challenges: Medical device approval processes are complex and uncertain. Market adoption: Customers may be slower to adopt new technology than projected. Competition: Larger companies could enter the market with competing products. Funding risk: Epinal may need to raise additional capital, which could dilute your ownership.

We are currently in the R&D and field trial phase. Our projected timeline is: 2026: Complete multi-state field trials and submit FDA application 2027: Achieve FDA clearance and launch limited commercial production 2028: Scale manufacturing and begin widespread sales

No. Investments in Epinal are equity investments, not charitable donations, and are therefore not tax-deductible. However, you may be eligible for certain tax benefits under the Qualified Small Business Stock (QSBS) exemption if Epinal meets IRS criteria and you hold shares for 5+ years. Consult a tax advisor for details.